Livanova Plc Stock Price, News & Analysis

LivaNova PLC (NASDAQ:LIVN) has priced an underwritten offering of 3,636,364 ordinary shares at $82.50 each, with a potential additional 545,454 shares. The net proceeds are projected to be about $280.1 million, aiming to partially repay a $450 million senior secured term loan. This offering is set to close on August 6, 2021, and is backed by an effective shelf registration statement. Goldman Sachs, Barclays, and UBS are the joint bookrunners, with shares available solely to qualified investors.

LivaNova PLC (NASDAQ:LIVN) has announced an underwritten offering of $300 million of ordinary shares, with an option for underwriters to purchase an additional 15%. Proceeds will be used to help repay a $450 million senior secured term loan, which incurred $9.7 million in interest expenses in Q2 2021. The offering is conducted under an effective shelf registration statement with the SEC. Joint bookrunners include Goldman Sachs, Barclays, and UBS.

LivaNova PLC (NASDAQ: LIVN) reported a strong performance for Q2 2021, with worldwide sales increasing 45.2% to $264.5 million. Excluding the divested Heart Valves business, sales rose 51.6% to $249.8 million. Neuromodulation sales surged 102.4%, reflecting a recovery in procedure volumes. However, the company posted a GAAP loss per share of $1.13. LivaNova has updated its 2021 guidance, anticipating net sales growth of 5-10% and adjusted earnings per share of $1.60-$1.90. Alex Shvartsburg has been appointed CFO, effective August 1, bringing 25 years of industry experience.

LivaNova PLC (NASDAQ:LIVN) will host a conference call to discuss its second quarter 2021 results on July 28, 2021, at 1 p.m. London time (8 a.m. EDT). The results will be released prior to the call. A live audiocast will be accessible on the company’s website. Participants are encouraged to log on 10 minutes early for setup. To join by phone, dial 844-558-0159 (U.S./Canada) or 236-714-3182 (international) with conference ID 3308297. Replays will be available for 90 days.

LivaNova PLC (NASDAQ:LIVN) has received FDA approval to launch the OSPREY clinical study for its aura6000® System, aimed at treating moderate to severe obstructive sleep apnea (OSA). This system provides a less restrictive alternative to CPAP machines by using an implantable pulse generator to stimulate the hypoglossal nerve, helping keep airways open during sleep. The randomized controlled trial will take place at about 20 sites across the U.S. and enroll up to 150 patients. OSA affects roughly one billion people globally, creating a significant market opportunity for innovative treatments.

LivaNova PLC (NASDAQ:LIVN) has completed the initial closing of its heart valve (HV) business divestiture to Gyrus Capital for €60 million (approx. $73 million). This strategic move allows LivaNova to concentrate on its core cardiovascular and neuromodulation markets. The HV business, expected to generate $70 million in net revenues, will transition 850 employees to Gyrus's newly formed company, CORCYM. Post-divestiture, LivaNova anticipates full-year adjusted EPS between $1.31 to $1.81, reflecting a dilution of approximately $0.09 due to the sale.

LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the UBS Global Healthcare Virtual Conference on May 25 at 8 a.m. ET. This presentation is accessible to the public via a live webcast on the LivaNova website. Interested listeners are advised to log in 10 minutes early for setup. The webcast will be available for replay for 30 days following the event. LivaNova, headquartered in London, is a leading medical technology company dedicated to improving patient lives globally with a workforce of approximately 4,000 employees.

LivaNova PLC (NASDAQ: LIVN) reported a 2.1% increase in worldwide sales for Q1 2021, totaling $247.6 million, but a decline of 0.4% on a constant-currency basis. The company experienced a diluted loss per share of $0.61 under GAAP, while adjusted diluted EPS was $0.35, up from $0.33 in Q1 2020. Notably, Neuromodulation sales rose by 15.7%, while Cardiovascular sales fell by 9.4%. For 2021, LivaNova anticipates net sales growth between 8% and 13%, reaffirming its full-year guidance.

LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.